Mode
Text Size
Log in / Sign up
N/A Completed N=62 Randomized Quadruple-blind Treatment

Effects of Deep Brain Stimulation on Motor, Mood, and Cognitive Symptoms in Parkinson's Disease

Source: ClinicalTrials.gov NCT00360009 ↗
Enrolled (actual)
62
Serious AEs
22.6%
Results posted
Feb 2010
Primary outcomePrimary: Change in Mean T-score of Visual Analogue Mood Scales (VAMS) Angry State — 5.3; -0.1 T-score

Summary

The purpose of this trial is to study the mood and cognitive effects of deep brain stimulation in Parkinson's disease.

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Mean T-score of Visual Analogue Mood Scales (VAMS) Angry State
5.3; -0.1 —
PRIMARY
Change in Visual Analogue Mood Scales (VAMS) Afraid State
1.3; -2.2 —
PRIMARY
Change in Visual Analogue Mood Scales (VAMS) Confused State
5.7; 1.3 —
PRIMARY
Change in Visual Analogue Mood Scales (VAMS) Energetic State
-1.4; 2.0 —
PRIMARY
Change in Visual Analogue Mood Scales (VAMS) Happy State
2.9; 5.0 —
PRIMARY
Change in Visual Analogue Mood Scales (VAMS) Sad State
-2.4; -1.0 —
PRIMARY
Change in Visual Analogue Mood Scales (VAMS) Tense State
-2.0; -8.5 —
PRIMARY
Change in Visual Analogue Mood Scales (VAMS) Tired State
-8.5; -2.0 —
SECONDARY
Change in Spielberger State-Trait Anxiety Inventory (STAI)
-3.3; 0.3 —
SECONDARY
Change in Beck Depression Inventory (BDI)
-2.8; -4.6 —
SECONDARY
Change in Letter Fluency Tasks (LFT)
-5.6; 0.3 —

Eligibility Criteria

Inclusion Criteria

  • Intractable, disabling PD with motor fluctuations, dyskinesias, or freezing episodes
  • Age between 30-75 years
  • Unsatisfactory clinical response to maximal medical management (with trials of both higher and lower doses of anti-Parkinsonian drugs)
  • A stable and optimal medical regimen of anti-Parkinsonian drug therapy for at least three months prior to surgery
  • Patients must be right-handed to be included in the study since mood and cognition are being analyzed and right hemisphere dominant patients could confound the results.

Exclusion Criteria

  • Clinically significant medical disease that would increase risk of developing pre- or postoperative complications (e.g., significant cardiac or pulmonary disease, uncontrolled hypertension)
  • Evidence of secondary or atypical parkinsonism as suggested by the presence of any of the following: 1) history of stroke(s), 2) exposure to toxins or neuroleptics, 3) history of encephalitis, 4) neurological signs of upper motor neuron disease, cerebellar involvement, supranuclear gaze palsy, or significant orthostatic hypotension
  • MRI scan with significant evidence of brain atrophy or other abnormalities (e.g., lacunar infarcts or iron deposits in the putamen)
  • The Mattis Dementia Rating Scale will be used to assess the level of intellectual function and patients will be excluded with scores reflecting clinical dementia
  • A major psychiatric disorder on the Structured Clinical Interview for DSM-IV (SCID-IV).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00360009). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search